You are here

Robert Hilgraf


Krenitsky VP, Nadolny L, Delgado M, et al. Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. Bioorg Med Chem Lett. 2012;22(3):1433–1438. . Epub 2011 Dec 10.

Krenitsky VP, Delgado M, Nadolny L, et al. Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury. Bioorg Med Chem Lett. 2012;22(3):1427–1432.

Hilgraf R, Pfaltz A. Chiral Bis(N-sulfonylamino)phosphine- and TADDOL-phosphite-oxazoline ligands: synthesis and application in asymmetric catalysis. Adv Synth Catal. 2005;347(1):61–77.

Wang Q, Chan TR, Hilgraf R, et al. Bioconjugation by copper(I)-catalyzed azide-alkyne [3 + 2] cycloaddition. J Am Chem Soc. 2003;125(11):3192–3193.

Robert Hilgraf, Ph.D.

Robert Hilgraf is director of the Medicinal Chemistry and Analytical/ADME Groups in the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard. His key focus is translating the research done at the Broad Institute and other academic institutions into compounds entering the clinic and ultimately the market to help patients. The Medicinal Chemistry team is supporting a number of different projects covering a broad range of therapeutic areas, from target validation, to optimizing screening hits through the different phases of a drug discovery program, to candidate selection for IND compounds. The Analytical and ADME group supports the discovery and development of small molecule projects by providing a number of different assays, like purity, plasma and metabolic stability, PPB, permeability, and others. The group works closely with all project teams and the chemistry group.

Prior to joining the Broad Institute in 2016, Hilgraf was a principal scientist at Celgene/Signal Pharmaceuticals in San Diego. While at Celgene, he was instrumental in moving four compounds towards clinical development, and two of these clinical candidates have advanced to Phase 2 clinical trials for fibrotic diseases. Before working in industry, he completed his postdoctoral studies with Nobel Laureate K. Barry Sharpless at the Scripps Research Institute in La Jolla, CA, developing a novel "Click Chemistry" bioconjugation method that is now widely used throughout both industry and academia.

Hilgraf obtained his Ph.D. in chemistry from the University of Basel, Switzerland, under the guidance of Prof. Andreas Pfaltz. He also earned his diploma (M.S.) in chemistry from the University of Hamburg with Prof. Wittko Francke.

Contact Robert Hilgraf at

May 2018